Peptides: Medicine’s Next Frontier—or the Wild West of Wellness?
- Chris
- 3 days ago
- 16 min read
BPC-157. TB-500. CJC-1295. Ipamorelin. MOTS-c. SS-31. The names sound more like rejected Star Wars characters than medicines, but peptide therapy may represent one of the more interesting frontiers in modern medicine.
Created by Christopher Caffrey, ACNP, PMHNP, Functional Medicine certified
August 3rd 2026
If you spend enough time around functional medicine, longevity clinics, CrossFit gyms, hormone practices, or men who own both a cold plunge and an infrared sauna, eventually somebody is going to start talking about peptides.
Usually with considerable enthusiasm.
One person says BPC-157 finally healed a tendon that had bothered him for three years. Someone else credits CJC-1295 and ipamorelin for better sleep and recovery. Another person is injecting MOTS-c because apparently taking care of your mitochondria with exercise, sleep, and good nutrition was no longer sufficiently complicated.
Then you search the medical literature and encounter a very different picture. Some of these compounds have legitimate human clinical trials behind them. Others have fascinating animal research but almost no meaningful human data. Several aren't FDA-approved, and some have essentially no established human safety profile at all.
So which version is correct?
The answer is uncomfortable but important: both contain some truth.
Peptide medicine is developing in real time. Some peptide therapies are already established medicines. Others are promising investigational compounds. And a few are essentially scientific hypotheses currently being sold as finished therapies.
That distinction matters.
My view of peptides is one of rational optimism. I think some of these molecules could become extremely useful tools over the next decade. But optimism becomes much more credible when we are willing to say, “We don't know yet.”
A promising mechanism is not the same thing as a clinical outcome. An impressive mouse study is not a human trial. A thousand enthusiastic testimonials are not pharmacovigilance.
At the same time, lack of FDA approval does not automatically mean a molecule is ineffective. Scientific discovery almost always precedes regulatory approval. Every approved drug spent part of its life being experimental.
The challenge is figuring out where on that journey each peptide actually sits.
First, Peptides Aren't New
The word peptide has somehow become synonymous with experimental injections obtained from a longevity clinic. Biologically, that makes little sense.
Peptides are relatively short chains of amino acids that often function as signaling molecules. Your body produces enormous numbers of them, and they participate in appetite, metabolism, reproduction, immune regulation, tissue repair, inflammation, hormone secretion, and cellular communication.
Modern medicine has also been using peptide-based drugs for decades. Insulin is one of the most obvious examples. More recently, GLP-1-based medications have demonstrated just how dramatically manipulating peptide signaling can alter appetite, glucose regulation, body weight, and metabolic disease.
So the idea that peptide signaling can produce powerful therapeutic effects is not speculative. We already know it can.
The question is whether the newer peptides showing up in functional and longevity medicine will eventually earn the same credibility.
Some are much closer than others.
An Evidence Ladder Makes More Sense Than “Peptides Work” or “Peptides Don't Work”
One of the biggest mistakes I see is discussing “peptide therapy” as though all peptides belong in the same bucket.
They don't. Insulin and BPC-157 are both peptides, but grouping them together clinically would be absurd. It would be like saying aspirin and an experimental rainforest plant are basically equivalent because both are molecules.
For this discussion, I find it useful to think about an informal evidence ladder.
At the top are FDA-approved peptide drugs with human clinical trials, established dosing, recognized adverse effects, and defined indications. Tesamorelin, bremelanotide, and now elamipretide belong somewhere in this category.
In the middle are peptides with meaningful human pharmacology or clinical research but without established approval for the purposes for which they are often promoted. CJC-1295, ipamorelin, thymosin alpha-1, full thymosin beta-4, and topical GHK-Cu fit in different places within this middle territory.
At the more experimental end are compounds such as BPC-157, TB-500, and MOTS-c, where the biological rationale may be fascinating but human therapeutic evidence remains limited or nearly nonexistent.
That does not mean everything at the bottom of the ladder will fail.
It means we shouldn't pretend it has already reached the top.
BPC-157: The Peptide Everyone Wants to Believe In
BPC-157 may currently be the celebrity of regenerative peptide medicine. It is promoted for tendon injuries, muscle injuries, ligament healing, joint pain, gastrointestinal injury, inflammation, and recovery.
The enthusiasm is not entirely fabricated. Preclinical research around BPC-157 has demonstrated interesting effects involving tissue repair, fibroblast activity, angiogenic signaling, and tendon healing. Animal and laboratory studies provide enough biological plausibility that I think BPC-157 deserves serious investigation rather than dismissal.
Human evidence, however, remains remarkably thin.
One small retrospective study examined intra-articular BPC-157 injections in patients with various types of knee pain. Most participants reported improvement, but the study was tiny, lacked a placebo group, was not blinded, and relied largely on subjective outcomes.[1]
The encouraging news is that the research is finally becoming more rigorous. A randomized, double-blind, placebo-controlled Phase II trial began in February 2026 evaluating subcutaneous BPC-157 in MRI-confirmed Grade II hamstring injuries. Researchers are measuring both return-to-sport time and structural healing on MRI, with study completion expected in 2027.[2]
That is exactly the kind of research we need. If BPC-157 accelerates human tissue repair, show it objectively.
What about safety? This is where confidence should decrease considerably. FDA states that compounded BPC-157 raises concerns involving immunogenicity, peptide impurities, and characterization, while human safety information remains inadequate to determine its risks.[3]
That does not mean BPC-157 has been proven dangerous. It means something much simpler: we do not yet have enough human exposure to know what its true adverse-effect profile looks like.
For now, I would describe BPC-157 as highly interesting, biologically plausible, and clinically immature.
TB-500: Similar Story, Important Distinction
TB-500 is often paired with BPC-157 in regenerative medicine protocols, particularly for tendons, ligaments, muscle injuries, and wound healing.
The science gets confusing because TB-500 is frequently discussed interchangeably with thymosin beta-4, even though they are not identical.
Thymosin beta-4 is a naturally occurring 43-amino-acid peptide involved in cell migration, inflammation, actin regulation, and tissue repair. Full thymosin beta-4 has actually been studied in humans. Small controlled studies of topical thymosin beta-4 have shown encouraging wound-healing signals in chronic venous ulcers and other difficult wounds.[4]
That is legitimate evidence.
But the compound commonly referred to as TB-500 is the LKKTETQ fragment of thymosin beta-4, not simply another name for the entire molecule.
FDA states that it has not identified human exposure data for drug products containing the TB-500 fragment and therefore lacks sufficient information to characterize its safety.[3]
This distinction is routinely lost online. Research on thymosin beta-4 does not automatically prove that injecting TB-500 produces the same effects in humans. They are related molecules, but related does not mean interchangeable.
I remain interested in the thymosin beta-4 pathway because the underlying regenerative biology is compelling. I am considerably less confident about claims that we already know how injectable TB-500 behaves clinically.
CJC-1295 and Ipamorelin: Turning Up the Growth Hormone Signal
CJC-1295 and ipamorelin are often paired because both influence growth-hormone secretion through different mechanisms.
CJC-1295 is a long-acting analog of growth-hormone-releasing hormone. Unlike many experimental peptides, we actually have controlled human pharmacology studies. In healthy adults, CJC-1295 produced dose-dependent increases in growth hormone lasting several days and increased IGF-1 approximately 1.5- to threefold. The estimated half-life was roughly six to eight days.[5]
So there is little question that CJC-1295 can alter human GH/IGF-1 physiology.
What is far less established is whether giving it to otherwise healthy adults meaningfully improves recovery, sleep, muscle mass, fat loss, or longevity enough to justify chronic exposure.
Ipamorelin works differently, acting as a ghrelin-receptor agonist and stimulating pulsatile growth-hormone release. Human pharmacokinetic and pharmacodynamic studies confirmed that effect, and ipamorelin was later studied as a potential treatment for postoperative ileus.[6]
Here is where physiology matters more than marketing.
Growth hormone and IGF-1 are not simply “youth hormones” that decline with age and therefore should automatically be restored upward. They are powerful growth signals. Excessive activity can contribute to edema, joint symptoms, carpal-tunnel-type symptoms, impaired glucose regulation, and other consequences.
FDA currently notes limited safety data for compounded CJC-1295 and reports serious adverse events including increased heart rate and systemic vasodilatory reactions. For ipamorelin, FDA cites peptide-characterization concerns and serious adverse events observed during an intravenous clinical trial, while noting inadequate safety information for other injectable routes.[3]
This does not mean the GH-secretagogue category is a dead end. I think it means we should treat it like endocrinology rather than a gym supplement.
Tesamorelin: What Happens When the Research Catches Up
Tesamorelin offers a useful comparison because it also stimulates the growth-hormone axis, but it actually made it through clinical development.
Tesamorelin is FDA-approved to reduce excess abdominal fat in adults with HIV-associated lipodystrophy. Randomized studies have demonstrated meaningful reductions in visceral adipose tissue, including approximately 18% reductions in some trials. Additional research has demonstrated reductions in liver fat in selected patients.[7]
This is not simply a theoretical mechanism. Researchers measured the fat.
But approval also brings something the peptide-wellness world doesn't always like talking about: a real safety profile.
Because tesamorelin increases GH and IGF-1 signaling, clinicians need to consider IGF-1 elevation, glucose intolerance, fluid retention, arthralgias, edema, and carpal-tunnel-type symptoms. Active malignancy is a contraindication, illustrating why manipulating growth signaling deserves respect rather than casual enthusiasm.
Tesamorelin gives us a useful lesson: peptide therapies can absolutely work, but when they become real medicines, they also acquire indications, contraindications, monitoring, and boundaries.
PT-141: Libido Biology Is More Than Blood Flow
PT-141, or bremelanotide, is another peptide frequently encountered in wellness medicine.
The FDA-approved pharmaceutical version, Vyleesi, is indicated for acquired, generalized hypoactive sexual desire disorder in certain premenopausal women. Two Phase III randomized trials demonstrated statistically significant improvements in sexual desire and reductions in associated distress.[8]
What makes bremelanotide interesting is that it acts through melanocortin signaling within the central nervous system rather than simply changing genital blood flow.
But it also has meaningful adverse effects. Nausea is common, and headache and flushing can occur. The medication can transiently increase blood pressure and decrease heart rate, while repeated exposure can cause focal hyperpigmentation. Its established FDA indication is also much narrower than the broad “libido peptide” marketing frequently seen online.
Again, the pattern repeats: once a peptide becomes a real medication, the conversation becomes considerably more nuanced.
GHK-Cu: Skin, Wound Healing, and the Problem With Changing the Route
GHK-Cu is a naturally occurring copper-binding tripeptide that has attracted considerable interest for skin health, collagen biology, wound repair, and hair.
There is actual human research here, particularly with topical formulations. In a randomized controlled study of diabetic neuropathic ulcers, a topical GHK-copper formulation increased wound closure compared with vehicle treatment.[9]
That makes topical copper peptides genuinely interesting.
It does not automatically make injectable GHK-Cu established therapy.
Changing the route of administration can completely change pharmacology, exposure, immune responses, and safety. FDA specifically identifies injectable GHK-Cu as having limited human safety information and raises concerns involving aggregation, peptide impurities, and immunogenicity.[3]
This is one of the recurring lessons in peptide medicine: evidence for the molecule is not necessarily evidence for the formulation you are being sold.
Dose matters. Route matters. Purity matters. Indication matters.
Thymosin Alpha-1: Immune Modulation Is More Interesting Than “Immune Boosting”
Thymosin alpha-1 is different from most of the recovery and longevity peptides because it has been studied extensively as an immune-modulating agent.
It has been investigated in infection, hepatitis, cancer adjunctive treatment, immunodeficiency, and critical illness and has therapeutic use in several countries, although it is not FDA-approved in the United States.
I prefer the term immune modulation here rather than “immune boosting.” You do not always want your immune system turned up louder. Someone with an autoimmune disease can explain why rather quickly.
The evidence also demonstrates how difficult immune modulation can be. A large randomized controlled trial published in 2025 found no clear evidence that thymosin alpha-1 reduced 28-day mortality in adults with sepsis.[10]
That negative result does not mean thymosin alpha-1 has no biological activity. It tells us that manipulating a complex immune network is not as simple as increasing one signal and expecting every patient to improve.
FDA currently states that information remains inadequate to completely characterize the risks of compounded thymosin alpha-1, including potential immunogenicity and peptide-characterization concerns.[3]
I think thymosin alpha-1 remains scientifically interesting. I simply would not describe it as a generic wellness peptide for “strengthening the immune system.”
MOTS-c: Mitochondria Sending Messages to the Rest of the Cell
MOTS-c is one of the peptides I find most intellectually interesting.
Unlike most peptides discussed here, MOTS-c is encoded within mitochondrial DNA. Research suggests that it participates in communication between mitochondrial metabolism and the rest of the cell. In experimental models, MOTS-c influences AMPK signaling, glucose metabolism, insulin sensitivity, and metabolic homeostasis.[11]
Researchers have even demonstrated that MOTS-c can move into the nucleus under metabolic stress and influence nuclear gene expression. Think about that for a moment: a peptide encoded within mitochondria appears capable of participating in communication with the cell's nuclear genome.[12]
That is remarkable biology.
Human research also shows that naturally occurring MOTS-c responds to exercise, further supporting the idea that it participates in metabolic adaptation.[13]
But here is the distinction that matters: observing endogenous MOTS-c in humans is not the same as proving that injecting synthetic MOTS-c improves insulin sensitivity, exercise performance, body composition, mitochondrial health, or longevity. FDA currently states that it has not identified human exposure data involving administered MOTS-c drug products and therefore cannot adequately characterize its safety.[3]
That puts MOTS-c in what I would call the “I really hope this works, but show me the trial” category.
Its future could be fascinating. Its present clinical evidence is not there yet.
SS-31: The Mitochondrial Peptide That Just Crossed the Finish Line
SS-31 deserves special attention because something important happened in September 2025.
SS-31, also known as elamipretide, went from being an experimental mitochondrial peptide discussed for years in research circles to becoming an FDA-approved medication.
The FDA granted accelerated approval to elamipretide under the brand name Forzinity for improving muscle strength in adults and children weighing at least 30 kilograms with Barth syndrome, a rare genetic mitochondrial disease.[14]
This is important far beyond Barth syndrome.
Elamipretide is a small mitochondrial-targeting peptide that binds cardiolipin, a phospholipid concentrated in the inner mitochondrial membrane. According to its FDA-approved labeling, it localizes to that membrane and improves mitochondrial morphology and function.
Cardiolipin is deeply involved in maintaining the organization and function of the electron-transport machinery. In other words, instead of simply giving the mitochondria more substrate, elamipretide appears to interact with part of the structural environment in which mitochondrial energy production occurs.
For a functional-medicine clinician interested in mitochondrial dysfunction, this is an extraordinarily interesting therapeutic concept.
But SS-31 also gives us perhaps the best lesson in this entire article about how complicated evidence can be.
The randomized trial that supported its development enrolled only 12 patients with Barth syndrome. In the initial placebo-controlled portion, elamipretide did not outperform placebo on the two primary endpoints, the six-minute walk test and fatigue score. Improvements in knee-extensor strength appeared later during the long-term open-label extension, and FDA granted accelerated approval based on that intermediate endpoint while requiring confirmatory evidence of clinical benefit.
That is neither a spectacular success nor a failure.
It is what real science often looks like in rare disease: tiny patient populations, imperfect endpoints, biologically compelling treatments, mixed trial results, and regulators deciding whether the totality of evidence justifies access while more evidence is collected.
Elamipretide has also been tested in primary mitochondrial myopathy. A large Phase III trial failed to improve six-minute walking distance or fatigue compared with placebo across the overall study population, although later analyses suggested that certain genetic subgroups may respond differently.[15]
That possibility—that mitochondrial therapies may work only in particular biological phenotypes—is exactly where precision and functional medicine may eventually converge.
As for safety, the FDA-approved formulation gives us information most experimental peptides simply don't have. Injection-site reactions are extremely common, and hypersensitivity reactions can occur. Eosinophil counts may also rise during prolonged treatment. Elamipretide and its metabolites are excreted through the kidneys, and the approved dose is reduced in adults with severe renal impairment.
What SS-31 does not prove is that everyone with fatigue, long COVID, brain fog, aging mitochondria, or poor exercise recovery should start injecting elamipretide.
Forzinity is approved for a very specific mitochondrial disease.
Still, conceptually, its approval is a major milestone. A medication is now targeting mitochondrial membrane biology rather than merely treating a downstream symptom of mitochondrial dysfunction.
That is worth paying attention to.
The Side Effect We Don't Know About Yet
Whenever someone tells me an experimental peptide has “no side effects,” my first question is how many humans have taken it and for how long.
If a drug has been studied in tens of thousands of people through multiple clinical trials and years of post-marketing surveillance, uncommon adverse effects eventually start appearing.
If 200 people have taken an experimental peptide, the absence of a serious adverse event tells us very little.
There are two possible explanations: the peptide is remarkably safe, or we simply haven't exposed enough humans for long enough to discover the problem.
Early in drug development, those two possibilities can look exactly the same.
There is another issue that receives too little attention: the molecule is only part of the product. Peptides can degrade, aggregate, contain synthesis-related impurities, or be incorrectly concentrated. Sterility matters. Cold-chain handling matters. The source of the active pharmaceutical ingredient matters.
This is why I have a very different reaction to a medication produced under pharmaceutical manufacturing standards than I do to a vial purchased online labeled “RESEARCH USE ONLY.”
You are now conducting a clinical trial with an enrollment of one, except nobody is checking the protocol.
What Should Safety Monitoring Look Like?
There is no universal “peptide panel.” Monitoring should follow the biology of the molecule being used.
For compounds affecting the GH/IGF-1 axis, clinicians should think about IGF-1 levels, glucose regulation, HbA1c, blood pressure, edema, joint symptoms, carpal-tunnel symptoms, sleep-apnea risk, and malignancy history.
For bremelanotide, cardiovascular history and blood pressure matter because of its acute hemodynamic effects.
For elamipretide, renal function, injection reactions, hypersensitivity symptoms, and potentially eosinophil trends become relevant based on the approved prescribing information.
For BPC-157, TB-500, MOTS-c, and other highly experimental compounds, the uncomfortable answer is that we do not completely know what should be monitored.
A normal CBC and metabolic panel do not prove that an inadequately studied peptide is safe.
You cannot lab-test your way out of missing clinical trials.
That is why patient selection, medical history, medication review, cancer history, pregnancy status, cardiovascular risk, kidney and liver function, treatment duration, product sourcing, and ongoing reassessment all matter.
Functional medicine should personalize treatment, but personalization should not become an excuse to abandon basic pharmacology.
Where I Think Peptide Medicine Is Going
This is the part that makes me optimistic.
Much of traditional pharmacology works by blocking something. We block receptors, enzymes, inflammation, stomach acid, cholesterol synthesis, or neurotransmitter reuptake.
Peptides increasingly give us the opportunity to manipulate signals.
We may eventually be able to tell a tissue to repair itself more efficiently, modulate a particular immune response, change metabolic signaling, alter mitochondrial behavior, influence appetite, increase regenerative activity, or stimulate a hormone in a more physiologically coordinated fashion.
The GLP-1 revolution has already shown what can happen when peptide biology, medicinal chemistry, and rigorous clinical research finally converge.
Elamipretide gives us another glimpse of the future: targeting mitochondrial structure and function directly.
Over the next decade, I expect we will see better peptide stabilization, more tissue-specific targeting, improved delivery systems, longer half-lives, and far more sophisticated use of mitochondrial and regenerative signaling.
Some of today's popular peptides will undoubtedly fail.
Others may turn out to work but produce unacceptable adverse effects.
Some will probably disappear quietly, the way many exciting therapies have disappeared before them.
But I would be surprised if none of the experimental peptides being discussed today eventually become mainstream therapies.
The interesting question is which ones survive the research.
Where I Land
I don't think peptide medicine is snake oil, and I don't think it is the miracle cure its most enthusiastic supporters sometimes portray.
It is something more interesting than either extreme.
It is an emerging field.
Tesamorelin and MOTS-c should not be discussed as though they have equivalent evidence. Bremelanotide and TB-500 are not in the same category. Topical GHK-Cu research does not automatically validate injectable GHK-Cu. Endogenous MOTS-c physiology does not establish injected MOTS-c therapy.
And perhaps most importantly, SS-31 reminds us that today's experimental peptide can become tomorrow's FDA-approved medication.
That doesn't mean every experimental peptide deserves to be used today. It means dismissing the entire field because some compounds are poorly studied would be just as intellectually lazy as prescribing everything because the mechanism sounds exciting.
Good functional medicine should be particularly comfortable in this territory. We should be willing to examine emerging therapies before every question has been answered while remaining disciplined enough to distinguish what we know, what we think we know, and what we simply hope is true.
When I look at a peptide, these are the questions I want answered:
Does the mechanism make biological sense?
Do human data exist?
Were the outcomes objective or subjective?
Was there a placebo group?
How many people have actually received the compound?
What do we know about short- and long-term safety?
Is the formulation being used actually the formulation that was studied?
Can meaningful risks be monitored?
Is there already a better-established treatment that accomplishes the same thing?
Is the potential benefit large enough for this particular patient to justify the remaining uncertainty?
That is not anti-peptide thinking.
It is how a promising field becomes responsible medicine.
Peptides may prove to be one of the more important therapeutic developments of the next decade. Mitochondrial peptides, regenerative peptides, immune-modulating peptides, and metabolic signaling molecules all deserve serious investigation.
But the correct response to an exciting frontier is not blind enthusiasm. It is curiosity with guardrails.
And right now, that is exactly where peptide medicine stands. The science is still evolving, but the potential is real—and I’m enthusiastic about helping patients navigate these therapies thoughtfully, safely, and with a clear understanding of what we know and what we still don’t.
References
1. Lee E, Padgett B. Intra-Articular Injection of BPC 157 for Multiple Types of Knee Pain. Alternative Therapies in Health and Medicine. 2021;27(4):8-13. PMID: 34324435.
2. ClinicalTrials.gov. A Randomized, Double-Blind, Placebo-Controlled Phase 2 Trial of Pentadecapeptide BPC 157 for Accelerated Repair of Acute Grade II Hamstring Strain Confirmed by MRI. NCT07437547. Study initiated February 2026.
3. U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Includes BPC-157, CJC-1295, injectable GHK-Cu, ipamorelin, MOTS-c, thymosin alpha-1, and TB-500.
4. Guarnera G, DeRosa A, Camerini R. Thymosin beta-4 and venous ulcers: clinical remarks on a European prospective, randomized study. Annals of the New York Academy of Sciences. 2007.
5. Teichman SL, Neale A, Lawrence B, et al. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295 in healthy adults. Journal of Clinical Endocrinology & Metabolism. 2006;91(3):799-805. doi:10.1210/jc.2005-1536.
6. Gobburu JVS, et al. Pharmacokinetic-pharmacodynamic modeling of ipamorelin, a growth hormone releasing peptide, in healthy volunteers. 1999.
7. Falutz J, Allas S, Blot K, et al. Effects of tesamorelin, a growth hormone-releasing factor, in HIV-infected patients with abdominal fat accumulation. Journal of Clinical Endocrinology & Metabolism. 2010.
8. Kingsberg SA, Clayton AH, Portman D, et al. Bremelanotide for the Treatment of Hypoactive Sexual Desire Disorder: Two Randomized Phase 3 Trials. Obstetrics & Gynecology. 2019. PMID: 31599840.
9. Mulder GD, Patt LM, Sanders L, et al. Enhanced healing of ulcers in patients with diabetes by topical treatment with glycyl-L-histidyl-L-lysine copper. Wound Repair and Regeneration. 1994;2(4):259-269.
10. Wu J, et al. The efficacy and safety of thymosin α1 for sepsis (TESTS): randomized controlled trial. 2025. PMID: 39814420.
11. Lee C, Zeng J, Drew BG, et al. The mitochondrial-derived peptide MOTS-c promotes metabolic homeostasis and reduces obesity and insulin resistance. Cell Metabolism. 2015;21(3):443-454.
12. Kim KH, Son JM, Benayoun BA, et al. The Mitochondrial-Encoded Peptide MOTS-c Translocates to the Nucleus to Regulate Nuclear Gene Expression in Response to Metabolic Stress. Cell Metabolism. 2018;28(3):516-524.e7.
13. Reynolds JC, Lai RW, Woodhead JST, et al. MOTS-c is an exercise-induced mitochondrial-encoded regulator of age-dependent physical decline and muscle homeostasis. Nature Communications. 2021.
14. U.S. Food and Drug Administration. FDA Grants Accelerated Approval to First Treatment for Barth Syndrome. Forzinity (elamipretide). September 19, 2025.
15. Karaa A, Haas R, Goldstein A, et al. Efficacy and Safety of Elamipretide in Individuals With Primary Mitochondrial Myopathy: The MMPOWER-3 Randomized Clinical Trial. 2023.
16. U.S. Food and Drug Administration. FORZINITY (elamipretide) Prescribing Information. Initial U.S. approval 2025.
Comments